

Norman Stockbridge

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10735630/publications.pdf>

Version: 2024-02-01

72
papers

5,136
citations

136950

32
h-index

91884

69
g-index

77
all docs

77
docs citations

77
times ranked

5790
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Methods for Employing Information About Uncertainty of Ascertainment of Events in Clinical Trials. Therapeutic Innovation and Regulatory Science, 2021, 55, 197-211. | 1.6 | 2 |
| 2 | Challenges of Cardio-Kidney Composite Outcomes in Large-Scale Clinical Trials. Circulation, 2021, 143, 949-958. | 1.6 | 15 |
| 3 | Standardized definitions for evaluation of heart failure therapies: scientific expert panel from the Heart Failure Collaboratory and Academic Research Consortium. European Journal of Heart Failure, 2020, 22, 2175-2186. | 7.1 | 23 |
| 4 | Conduct of Clinical Trials in the Era of COVID-19. Journal of the American College of Cardiology, 2020, 76, 2368-2378. | 2.8 | 35 |
| 5 | Standardized Definitions for Evaluation of Heart Failure Therapies: Scientific Expert Panel From the Heart Failure Collaboratory and Academic Research Consortium. JACC: Heart Failure, 2020, 8, 961-972. | 4.1 | 15 |
| 6 | Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI. Journal of the American College of Cardiology, 2020, 76, 1468-1483. | 2.8 | 35 |
| 7 | Effects of Electrical Stimulation on hiPSC-CM Responses to Classic Ion Channel Blockers. Toxicological Sciences, 2020, 174, 254-265. | 3.1 | 12 |
| 8 | Endpoints in Heart Failure Drug Development. JACC: Heart Failure, 2020, 8, 429-440. | 4.1 | 28 |
| 9 | Ask the Expert: A Regulatory Perspective on Clinical Trials for Pulmonary Arterial Hypertension. Advances in Pulmonary Hypertension, 2020, 19, 62-65. | 0.1 | 1 |
| 10 | Design of a "Lean" Case Report Form for Heart Failure Therapeutic Development. JACC: Heart Failure, 2019, 7, 913-921. | 4.1 | 6 |
| 11 | Detection of T Wave Peak for Serial Comparisons of JTp Interval. Frontiers in Physiology, 2019, 10, 934. | 2.8 | 12 |
| 12 | Errors of Fixed QT Heart Rate Corrections Used in the Assessment of Drug-Induced QTc Changes. Frontiers in Physiology, 2019, 10, 635. | 2.8 | 18 |
| 13 | Workshop Report. Circulation Research, 2019, 125, 855-867. | 4.5 | 53 |
| 14 | Heart Rate Correction of the J-to-Tpeak Interval. Scientific Reports, 2019, 9, 15060. | 3.3 | 10 |
| 15 | New Strategies for the Conduct of Clinical Trials in Pediatric Pulmonary Arterial Hypertension: Outcome of a Multistakeholder Meeting With Patients, Academia, Industry, and Regulators, Held at the European Medicines Agency on Monday, June 12, 2017. Journal of the American Heart Association, 2019, 8, e011306. | 3.7 | 23 |
| 16 | Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. European Heart Journal, 2019, 40, 2632-2653. | 2.2 | 335 |
| 17 | Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention. Circulation, 2019, 140, 240-261. | 1.6 | 428 |
| 18 | Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus. Circulation, 2019, 140, 2108-2118. | 1.6 | 22 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Assessment of Multi-Channel Block in a Phase I Randomized Study Design: Results of the Phase I ECG Biomarker Validation Study. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 943-953. | 4.7 | 66 |
| 20 | Implications of Individual QT/RR Profiles”Part 2: Zero QTc/RR Correlations Do Not Prove QTc Correction Accuracy in Studies of QTc Changes. <i>Drug Safety</i> , 2019, 42, 415-426. | 3.2 | 5 |
| 21 | Implications of Individual QT/RR Profiles”Part 1: Inaccuracies and Problems of Population-Specific QT/Heart Rate Corrections. <i>Drug Safety</i> , 2019, 42, 401-414. | 3.2 | 14 |
| 22 | Cardiovascular outcome trials in patients with chronic kidney disease: challenges associated with selection of patients and endpoints. <i>European Heart Journal</i> , 2019, 40, 880-886. | 2.2 | 34 |
| 23 | Drug-induced Proarrhythmia and Torsade de Pointes: A Primer for Students and Practitioners of Medicine and Pharmacy. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 997-1012. | 2.0 | 28 |
| 24 | Improving Heart Failure Therapeutics Development in the United States. <i>Journal of the American College of Cardiology</i> , 2018, 71, 443-453. | 2.8 | 40 |
| 25 | Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1379-1390. | 2.8 | 50 |
| 26 | Mechanistic Model-Informed Proarrhythmic Risk Assessment of Drugs: Review of the CiPA Initiative and Design of a Prospective Clinical Validation Study. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 54-66. | 4.7 | 106 |
| 27 | International Multisite Study of Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Drug Proarrhythmic Potential Assessment. <i>Cell Reports</i> , 2018, 24, 3582-3592. | 6.4 | 254 |
| 28 | Heart Failure With Preserved Ejection Fraction Expert Panel Report. <i>JACC: Heart Failure</i> , 2018, 6, 619-632. | 4.1 | 103 |
| 29 | Importance of QT/RR hysteresis correction in studies of drug-induced QTc interval changes. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2018, 45, 491-503. | 1.8 | 15 |
| 30 | Evaluation of Batch Variations in Induced Pluripotent Stem Cell-Derived Human Cardiomyocytes from 2 Major Suppliers. <i>Toxicological Sciences</i> , 2017, 156, kfw235. | 3.1 | 45 |
| 31 | Can Bias Evaluation Provide Protection Against False-Negative Results in QT Studies Without a Positive Control Using Exposure-Response Analysis?. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 85-95. | 2.0 | 20 |
| 32 | The FDA in the 21st Century. <i>JACC: Heart Failure</i> , 2017, 5, 67-70. | 4.1 | 2 |
| 33 | Long-term electrocardiographic safety monitoring in clinical drug development: A report from the Cardiac Safety Research Consortium. <i>American Heart Journal</i> , 2017, 187, 156-169. | 2.7 | 11 |
| 34 | Reassessing Phase II Heart Failure Clinical Trials. <i>Circulation: Heart Failure</i> , 2017, 10, . | 3.9 | 14 |
| 35 | Utility of Model-Based Approaches for Informing Dosing Recommendations in Specific Populations: Report From the Public AAPS Workshop. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 105-109. | 2.0 | 12 |
| 36 | 2017 ACC/AAP/AHA Health Policy Statement on Opportunities and Challenges in Pediatric Drug Development: Learning From Sildenafil. <i>Journal of the American College of Cardiology</i> , 2017, 70, 495-503. | 2.8 | 2 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 37 | 2017 ACC/AAP/AHA Health Policy Statement on Opportunities and Challenges in Pediatric Drug Development: Learning From Sildenafil. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017, 10, . | 2.2 | 3 |
| 38 | The Evolving Roles of Human iPSC-Derived Cardiomyocytes in Drug Safety and Discovery. <i>Cell Stem Cell</i> , 2017, 21, 14-17. | 11.1 | 69 |
| 39 | Comprehensive Translational Assessment of Human-Induced Pluripotent Stem Cell Derived Cardiomyocytes for Evaluating Drug-Induced Arrhythmias. <i>Toxicological Sciences</i> , 2017, 155, 234-247. | 3.1 | 213 |
| 40 | Resourcing Drug Development Commensurate With its Public Health Importance. <i>JACC Basic To Translational Science</i> , 2016, 1, 309-312. | 4.1 | 4 |
| 41 | Evolving regulatory paradigm for proarrhythmic risk assessment for new drugs. <i>Journal of Electrocardiology</i> , 2016, 49, 837-842. | 0.9 | 24 |
| 42 | Exploring New Endpoints for Patients With Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016, 9, . | 3.9 | 46 |
| 43 | The Cardiac Safety Research Consortium enters its second decade: An invitation to participate. <i>American Heart Journal</i> , 2016, 177, 96-101. | 2.7 | 9 |
| 44 | The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative – Update on progress. <i>Journal of Pharmacological and Toxicological Methods</i> , 2016, 81, 15-20. | 0.7 | 335 |
| 45 | Evolution of strategies to improve preclinical cardiac safety testing. <i>Nature Reviews Drug Discovery</i> , 2016, 15, 457-471. | 46.4 | 323 |
| 46 | Universal Correction for QT/RR Hysteresis. <i>Drug Safety</i> , 2016, 39, 577-588. | 3.2 | 33 |
| 47 | A proposal for scientific framework enabling specific population drug dosing recommendations. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 1073-1078. | 2.0 | 39 |
| 48 | Moxifloxacin-induced QT interval prolongations in healthy male Japanese and Caucasian volunteers: a direct comparison in a thorough QT study. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 446-459. | 2.4 | 20 |
| 49 | Novel oral anticoagulants and reversal agents: Considerations for clinical development. <i>American Heart Journal</i> , 2015, 169, 751-757. | 2.7 | 69 |
| 50 | Early Drug Discovery Prediction of Proarrhythmia Potential and Its Covariates. <i>AAPS Journal</i> , 2015, 17, 1025-1032. | 4.4 | 22 |
| 51 | Sex differences in drug-induced changes in ventricular repolarization. <i>Journal of Electrocardiology</i> , 2015, 48, 1081-1087. | 0.9 | 8 |
| 52 | Centralized adjudication of cardiovascular end points in cardiovascular and noncardiovascular pharmacologic trials: A report from the Cardiac Safety Research Consortium. <i>American Heart Journal</i> , 2015, 169, 197-204. | 2.7 | 25 |
| 53 | Cardiac Safety Research Consortium (CSRC): Cardiovascular Safety and Adverse Event Case Report Forms. <i>Therapeutic Innovation and Regulatory Science</i> , 2015, 49, 511-513. | 1.6 | 1 |
| 54 | Improving cardiovascular clinical trials conduct in the United States: Recommendation from clinicians, researchers, sponsors, and regulators. <i>American Heart Journal</i> , 2015, 169, 305-314. | 2.7 | 20 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Cardiovascular Safety Outcome Trials: A meeting report from the Cardiac Safety Research Consortium. <i>American Heart Journal</i> , 2015, 169, 486-495. | 2.7 | 21 |
| 56 | Cardiovascular Drug Development. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1567-1582. | 2.8 | 168 |
| 57 | Implications of the IQ-CSRC Prospective Study: Time to Revise ICHÂ14. <i>Drug Safety</i> , 2015, 38, 773-780. | 3.2 | 52 |
| 58 | Comprehensive T wave Morphology Assessment in a Randomized Clinical Study of Dofetilide, Quinidine, Ranolazine, and Verapamil. <i>Journal of the American Heart Association</i> , 2015, 4, . | 3.7 | 115 |
| 59 | Topic of Timely Interestâ€”Decision Criteria for Negative QT Assessment Using Exposure Response Analysis of Data From Early-Phase Clinical Studies: Letter to the Editor. <i>Therapeutic Innovation and Regulatory Science</i> , 2015, 49, 717-719. | 1.6 | 1 |
| 60 | Lessons Learned From Hundreds of Thorough QT Studies. <i>Therapeutic Innovation and Regulatory Science</i> , 2015, 49, 392-397. | 1.6 | 13 |
| 61 | Personalized Cardiovascular Medicine Today. <i>Circulation</i> , 2015, 132, 1425-1432. | 1.6 | 33 |
| 62 | The IQâ€CSRC Prospective Clinical Phase 1 Study: â€œCan Early QT Assessment Using Exposure Response Analysis Replace the Thorough QT Study?â€• <i>Annals of Noninvasive Electrocardiology</i> , 2014, 19, 70-81. | 1.1 | 92 |
| 63 | Developing Therapies for Heart Failure WithÂPreservedÂEjection Fraction. <i>JACC: Heart Failure</i> , 2014, 2, 97-112. | 4.1 | 267 |
| 64 | Assessment of drug-induced increases in blood pressure during drug development: Report from the Cardiac Safety Research Consortium. <i>American Heart Journal</i> , 2013, 165, 477-488. | 2.7 | 30 |
| 65 | Dealing with Global Safety Issues. <i>Drug Safety</i> , 2013, 36, 167-182. | 3.2 | 134 |
| 66 | Thorough QT Studies and Indirect Causes of QTc Changes. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2012, 35, 1411-1412. | 1.2 | 3 |
| 67 | Implications of geographical variation on clinical outcomes of cardiovascular trials. <i>American Heart Journal</i> , 2012, 164, 303-312. | 2.7 | 44 |
| 68 | Practice and challenges of thorough QT studies. <i>Journal of Electrocardiology</i> , 2012, 45, 582-587. | 0.9 | 22 |
| 69 | The Cardiac Safety Research Consortium electrocardiogram warehouse: Thorough QT database specifications and principles of use for algorithm development and testing. <i>American Heart Journal</i> , 2010, 160, 1023-1028. | 2.7 | 26 |
| 70 | Assessing proarrhythmic potential of drugs when optimal studies are infeasible. <i>American Heart Journal</i> , 2009, 157, 827-836.e1. | 2.7 | 81 |
| 71 | Current challenges in the evaluation of cardiac safety during drug development: Translational medicine meets the Critical Path Initiative. <i>American Heart Journal</i> , 2009, 158, 317-326. | 2.7 | 113 |
| 72 | Concentrationâ€QT Relationships Play a Key Role in the Evaluation of Proarrhythmic Risk During Regulatory Review. <i>Journal of Clinical Pharmacology</i> , 2008, 48, 13-18. | 2.0 | 206 |